Emerging biomarkers such as NGAL, cystatin C, suPAR, TIMP-2, and IGFBP7 demonstrate superior sensitivity and specificity compared to traditional markers, enabling earlier CKD detection and improved patient stratification. This evidence concerns the gene CST3 and chronic kidney disease.